Two experimental drugs, luspatercept and sotatercept, have shown to be active in myelodysplastic syndrome (MDS), a type of cancer in which the bone marrow does not make enough healthy blood cells and there are abnormal (blast) cells in the blood and/or bone marrow.
In a healthy person, the bone marrow makes blood stem cells (immature cells) that become mature blood cells over time. A blood stem cell may become a lymphoid stem cell or a myeloid stem cell. A lymphoid stem cell becomes a white blood cell. A myeloid stem cell becomes one of three types of mature blood cells: red blood cell, platelet, or white blood cells.
In a patient with MDS, the blood stem cells (immature cells) do not become healthy red blood cells, white blood cells, or platelets. These immature blood cells, called blasts, do not work the way they should and either die in the bone marrow or soon after they go into the blood. This leaves less room for healthy white blood cells, red blood cells, and platelets to form in the bone marrow. When there are fewer healthy blood cells, infection, anemia, or easy bleeding may occur. Patients become dependent on transfusions to live.
Luspatercept and sotatercept are molecules that belong to a new class of anti-neoplastic compounds called activin receptor antagonists. The drugs are being developed by Acceleron and Celgene. Data reported at the 2014 American Hematologic Society meeting demonstrated:
Sotaterecept: 54-patient Phase II trial showed that 45% of patients with MDS experienced either a reduced need for transfusions or an increase in hemoglobin levels. Also, 19 of the 45 patients who were in the highly transfusion-dependent group prior to receiving sotatercept demonstrated a reduced need for transfusions, including five who became transfusion-independent.
Luspaterecept – Phase II data showed that 80% of patients with low transfusion burden (four of five) achieved the primary endpoint of hemoglobin increase, while and 25% of MDS patients with high transfusion burden achieved transfusion-independence.
Luspatercept: Phase II data in patients with beta-thalassemia Luspatercept increased haemoglobin levels, reduced transfusion burden and improved measures of iron overload and also two out of two patients who presented with persistent leg ulcers, a complication of beta-thalassemia, experienced rapid healing.
The most common type of thalassemia is beta thalassemia. It involves decreased production of normal adult hemoglobin (Hb A), the predominant type of hemoglobin from soon after birth until death. (All hemoglobin consists of two parts: heme and globin). The globin part of Hb A has 4 polypeptide chains. Two of these chains are identical and are designated the alpha chains. The other two chains are also identical to one another but differ from the alpha chains and are termed the beta chains. In persons with beta thalassemia, there is reduced or absent production of beta globin chains. Patients require repeated transfusions.
How do luspatercept and sotatercept work, and how do they differ? Both of them block signaling mediated by Transforming Growth Factor beta (TGF-β) on the Activin Receptor type IIA (ActRIIA). Activin receptor signaling by TGF-β inhibits osteoblast activity and induces osteoclast activity. By blocking Activin receptor signaling, bone loss is inhibited; this has the effect of reducing marrow crowding, which results in MDS.
Sotatercept binds to the ActRIIA and luspatercept binds to TGF-β:
Sotatercept is soluble fusion protein consisting of the extracellular domain of activin receptor type IIA (ActRIIA) linked to the Fc protein of human IgG1. Sotatercept binds with high affinity to activin A and other proteins in the TGF-β superfamily and inhibits signaling through the ActRIIA receptor.
Luspatercept is a ligand trap that binds to TGF-β.
With respect to its activity in beta-thalassemia, the mechanism by which luspatercept promotes erythropoiesis is not understood. However, in preclinical studies, luspatercept promoted red blood cell (RBC) formation in the absence of erythropoietin (EPO) signaling, had distinct effects from EPO on RBC differentiation, and acted on a different population of progenitor blood cells than EPO during RBC development.
So the companies have got two shots on goal in both areas. Steve Ertel, chief business officer at Acceleron, told PharmaTimes that “our plan with Celgene has been to study luspatercept and sotatercept in Phase II studies for MDS and beta-thalassemia “and select the optimal molecule between these two to take forward into Phase III trials. Sotatercept alone is in ongoing trials in chronic kidney disease.